IDEX/$IEX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About IDEX
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. The company generated $3.5 billion in revenue in 2025.
- Ticker
- $IEX
- Sector
- Industrials
- Primary listing
- NYSE
- Employees
- 8,700
- Headquarters
- Northbrook, United States
- Website
- www.idexcorp.com
IDEX Metrics
BasicAdvanced
$18B
33.24
$7.20
0.96
$2.90
1.22%
Price and volume
Market cap
$18B
Beta
0.96
52-week high
$243.80
52-week low
$160.60
Average daily volume
761K
Dividend rate
$2.90
Financial strength
Current ratio
2.778
Quick ratio
1.81
Long term debt to equity
0.436
Total debt to equity
0.436
Dividend payout ratio (TTM)
39.92%
Interest coverage (TTM)
12.53%
Profitability
EBITDA (TTM)
998.3
Gross margin (TTM)
44.91%
Net profit margin (TTM)
14.65%
Operating margin (TTM)
21.47%
Effective tax rate (TTM)
23.87%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
7.09%
Return on equity (TTM)
13.35%
Valuation
Price to earnings (TTM)
33.238
Price to revenue (TTM)
4.858
Price to book
4.39
Price to tangible book (TTM)
-36.41
Price to free cash flow (TTM)
26.638
Free cash flow yield (TTM)
3.75%
Free cash flow per share (TTM)
8.985
Dividend yield (TTM)
1.21%
Forward dividend yield
1.22%
Growth
Revenue change (TTM)
6.93%
Earnings per share change (TTM)
13.93%
3-year revenue growth (CAGR)
3.54%
10-year revenue growth (CAGR)
5.80%
3-year earnings per share growth (CAGR)
-3.96%
10-year earnings per share growth (CAGR)
7.03%
3-year dividend per share growth (CAGR)
-34.44%
10-year dividend per share growth (CAGR)
-6.15%
What the Analysts think about IDEX
Analyst ratings (Buy, Hold, Sell) for IDEX stock.
Analyst projections of the future price of IDEX stock.
Bulls say / Bears say
IDEX delivered 5% organic sales growth and 12% adjusted EPS growth in the second quarter, then raised its full-year organic growth and adjusted EPS outlook. That points to solid operating momentum and better earnings visibility. (IDEX Corporation)
Health & Science Technologies is benefiting from strong demand linked to data-centre power, semiconductors, and space and defence. Its second-quarter organic sales grew 12%, supporting the case that IDEX has exposure to expanding technology markets. (IDEX Corporation)
Orders rose by double digits organically in all three segments, with management reporting that some customers are booking capacity further ahead. If those orders convert to sales, they could extend growth beyond the current quarter. (The Motley Fool)
Some of the margin and earnings improvement came from a temporary tariff-refund benefit: refunds added 150 basis points to gross margin and $0.08 to adjusted EPS in the quarter. The boost may not recur. (IDEX Corporation)
Growth remains uneven: HST's 12% organic sales growth contrasted with 1% growth in Fluid & Metering Technologies and a 1% decline in Fire & Safety/Diversified Products. Weakness in energy, agriculture, chemicals, European rescue and dispensing markets weighed on the latter segments. (IDEX Corporation)
The shares carry a valuation premium: Simply Wall St put IDEX at 31.7 times earnings, against 25.4 times for the machinery industry. That leaves less room for disappointment if growth or earnings momentum fades. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
IDEX Financial Performance
Revenues and expenses
IDEX Earnings Performance
Company profitability
Upcoming events
No upcoming events
IDEX News
AllArticlesVideos
Funds containing IDEX
AllUSDEURGBP
Fund name | Fund size | $IEX weighting |
|---|---|---|
L&G Clean Water$GLUG | $772M | 1.97% |
L&G Clean Water£GLGG | $772M | 1.97% |
SPDR S&P 500 Low Volatility$LOWV | $113M | 0.86% |
SPDR S&P 500 Low Volatility£USLV | $113M | 0.86% |
Invesco S&P 500 Low Volatility£SPLG | $143M | 0.85% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.